Reacción a "A new drug shows efficacy against advanced endometrial cancer, according to a phase 3 trial"

The incidence of endometrial cancer has been rising in recent years. For patients diagnosed at an advanced stage, the prognosis is poor, with a progression-free survival of approximately 13 months when treated with standard chemotherapy (carboplatin and paclitaxel). The combination of immunotherapy and chemotherapy has shifted the treatment paradigm for advanced endometrial cancer, substantially increasing overall survival—particularly in patients with dMMR tumors (tumors with a deficiency in DNA mismatch repair).

However, the integration of immunotherapy into the first-line treatment setting has created an unmet need in subsequent lines of therapy. If the cancer progresses following chemo-immunotherapy, therapeutic options become limited, often restricted to single-agent chemotherapy, which yields response rates of less than 20%. In this context, SAC-TMT has demonstrated a clinically and statistically significant improvement in both progression-free survival and overall survival compared to conventional chemotherapy in patients with advanced or recurrent endometrial cancer that has progressed after platinum-based chemotherapy and immunotherapy, all while maintaining a tolerable safety profile. SAC-TMT is emerging as a standard-of-care treatment for this patient population, though careful consideration must be given to the drug’s toxicity and the fact that the follow-up period remains relatively short.